(iii) Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. International Journal of Biochemistry & Cell Biology; 2007, 39(7-8):1476-82.
(iv) Johnstone, RW. Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery; 2002, 1, 287 - 299.
(v) Lesko, E and Majka, M. The biological role of HGF-MET axis in tumor growth and developmentof metastasis. Fron Biooscie; 2008, 13: 1271-80.
(vi) Sattler, M and Salgia R. c-Met and hepatocyte growth factor; potential as novel targets in cancer theray. Curr Oncol Rep; 2007, 9 (2) 102-8.
(vii) Boccaccio C, and Comoglio, PM. Invasive growth; a MET driven genetic programme for cancer and stem cells. Nat Rev Cancer; 2007, 6(8) 637-45.
(viii) Peruzzi, B and Bottaro, DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res; 2006, 12(12) 3657-60.
Media Contact: William Foster, +1-908-541-4057, Investor Relations: Tina Pinto, +1-732-524-2034
Andalucía
Aragón
Cantabria
Castilla-La Mancha
Castilla y León
Catalunya
Extremadura
Galicia
Islas Canarias
Islas Baleares
Madrid
País Vasco
La Rioja
C. Valenciana
Navarra
Asturias
Murcia
Ceuta y Melilla
